{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:50:46Z","timestamp":1791489046773,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of cancer treatment, leading to early treatment cessation and long-lasting disability. This project aimed to determine acceptability and barriers of routine CIPN screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a prospective sample across two sites, patients scheduled for treatment or treated with neurotoxic therapy were eligible to complete CIPN screening at any cycle. Three brief patient-reported outcome screening tools (NCI-PRO-CTCAE, PNQ, and EviQ) and a short feasibility questionnaire were deployed (termed\u202f\n                      <jats:italic>CIPN-Screen)<\/jats:italic>\n                      during appointments (Centre 1) or via automated text messages (Centre 2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven hundred fifty-five screens were undertaken in 159 participants between March 2022 and November 2023, with 109 at Centre 1 (median[IQR] 1[1]screen) and 646 at Centre 2 (median[IQR] 8[6]screens). Automatic text message reminders at Centre 2 enabled longitudinal assessments to be collected. 426 screens (56.4%) identified CIPN symptoms with 138 (18.3%) moderate-to-severe. Most respondents reported that the CIPN-Screen was easy to complete (92.0%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009671), easy to understand (91.6%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009668), and helpful to describe symptoms (85.6%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009624). Acceptability did not differ by age, sex, or chemotherapy type; however, acceptability did differ according to CIPN symptom severity (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002). There were significant differences in CIPN symptom score over time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952), indicating that the CIPN-Screen detected symptom evolution over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Questionnaire-based CIPN screening is feasible and assists in symptom profiling for patients treated with neurotoxic chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for cancer survivors<\/jats:title>\n                    <jats:p>CIPN is an important toxicity with lasting effects for cancer survivors. Identifying better approaches to patient-relevant CIPN screening will enable improved care for cancer survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11296-4","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:22:11Z","timestamp":1791440531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN)"],"prefix":"10.1007","volume":"34","author":[{"given":"Alice","family":"Treloar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Grimison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"11296_CR1","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1007\/s10072-021-05576-6","volume":"42","author":"T Li","year":"2021","unstructured":"Li T, Mizrahi D, Goldstein D, Kiernan MC, Park SB (2021) Chemotherapy and peripheral neuropathy. Neurol Sci 42:4109\u20134121. https:\/\/doi.org\/10.1007\/s10072-021-05576-6","journal-title":"Neurol Sci"},{"key":"11296_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.6004\/jnccn.2021.7026","volume":"19","author":"E Battaglini","year":"2021","unstructured":"Battaglini E, Goldstein D, Grimison P, McCullough S, Mendoza-Jones P, Park SB (2021) Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes. J Natl Compr Canc Netw 19:821\u2013828. https:\/\/doi.org\/10.6004\/jnccn.2021.7026","journal-title":"J Natl Compr Canc Netw"},{"key":"11296_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","volume":"18","author":"N Denduluri","year":"2018","unstructured":"Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D et al (2018) Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 18:380\u2013386. https:\/\/doi.org\/10.1016\/j.clbc.2018.02.003","journal-title":"Clin Breast Cancer"},{"key":"11296_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102241","volume":"99","author":"DL Hertz","year":"2021","unstructured":"Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT et al (2021) Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN). Cancer Treat Rev 99. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102241","journal-title":"Cancer Treat Rev"},{"key":"11296_CR5","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133348. https:\/\/doi.org\/10.1200\/jco.20.01399","journal-title":"J Clin Oncol"},{"key":"11296_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306\u20131319. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.003","journal-title":"Ann Oncol"},{"key":"11296_CR7","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1007\/s00520-022-07024-3","volume":"30","author":"D Mizrahi","year":"2022","unstructured":"Mizrahi D, Goldstein D, Kiernan MC, Robinson L, Pitiyarachchi O, McCullough S et al (2022) Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Support Care Cancer 30:5965\u20135974. https:\/\/doi.org\/10.1007\/s00520-022-07024-3","journal-title":"Support Care Cancer"},{"key":"11296_CR8","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1007\/s00520-021-06196-8","volume":"29","author":"A Yu","year":"2021","unstructured":"Yu A, Street D, Viney R, Goodall S, Pearce A, Haywood P et al (2021) Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Support Care Cancer 29:6379\u20136387. https:\/\/doi.org\/10.1007\/s00520-021-06196-8","journal-title":"Support Care Cancer"},{"key":"11296_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24139","volume":"7","author":"T Li","year":"2024","unstructured":"Li T, Timmins HC, Mahfouz FM, Trinh T, Mizrahi D, Horvath LG et al (2024) Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Netw Open 7. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.24139","journal-title":"JAMA Netw Open"},{"key":"11296_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jpainsymman.2019.07.021","volume":"58","author":"JM McCrary","year":"2019","unstructured":"McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Friedlander M et al (2019) Optimizing clinical screening for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 58:1023\u20131032. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.07.021","journal-title":"J Pain Symptom Manage"},{"key":"11296_CR11","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244. https:\/\/doi.org\/10.1093\/jnci\/dju244","journal-title":"J Natl Cancer Inst"},{"key":"11296_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349. https:\/\/doi.org\/10.1053\/j.seminoncol.2005.12.010","journal-title":"Semin Oncol"},{"key":"11296_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-112","volume":"13","author":"JM Langton","year":"2013","unstructured":"Langton JM, Pesa N, Rushton S, Ward RL, Pearson S-A (2013) Uptake of a web-based oncology protocol system: how do cancer clinicians use eviQ cancer treatments online? BMC Cancer 13:1\u20139. https:\/\/doi.org\/10.1186\/1471-2407-13-112","journal-title":"BMC Cancer"},{"key":"11296_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson N, Heimans J, Muller M, Hildebrand J, Delattre J-Y et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135\u20131139. https:\/\/doi.org\/10.1016\/j.ejca.2005.02.012","journal-title":"Eur J Cancer"},{"key":"11296_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-5908-9-7","volume":"9","author":"CM Shea","year":"2014","unstructured":"Shea CM, Jacobs SR, Esserman DA, Bruce K, Weiner BJ (2014) Organizational readiness for implementing change: a psychometric assessment of a new measure. Implement Sci 9:1\u201315. https:\/\/doi.org\/10.1186\/1748-5908-9-7","journal-title":"Implement Sci"},{"key":"11296_CR16","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2003","unstructured":"Hinkle DE, Wiersma W, Jurs SG (2003) Applied statistics for the behavioral sciences. Houghton Mifflin, Boston"},{"key":"11296_CR17","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00520-020-05836-9","volume":"29","author":"L Geerligs","year":"2021","unstructured":"Geerligs L, Shepherd HL, Butow P, Shaw J, Masya L, Cuddy J et al (2021) What factors influence organisational readiness for change? Implementation of the Australian clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP). Support Care Cancer 29:3235\u20133244. https:\/\/doi.org\/10.1007\/s00520-020-05836-9","journal-title":"Support Care Cancer"},{"issue":"Suppl 2","key":"11296_CR18","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/jns.12333","volume":"24","author":"SB Park","year":"2019","unstructured":"Park SB, Alberti P, Kolb NA, Gewandter JS, Schenone A, Argyriou AA (2019) Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(Suppl 2):S13\u2013S25. https:\/\/doi.org\/10.1111\/jns.12333","journal-title":"J Peripher Nerv Syst"},{"key":"11296_CR19","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","volume":"25","author":"JM McCrary","year":"2017","unstructured":"McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC et al (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer 25:3485\u20133493. https:\/\/doi.org\/10.1007\/s00520-017-3772-y","journal-title":"Support Care Cancer"},{"key":"11296_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s41687-021-00377-z","volume":"5","author":"R Knoerl","year":"2021","unstructured":"Knoerl R, Mazzola E, Mitchell SA, Hong F, Salehi E, McCleary N et al (2021) Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors. J Patient Rep Outcomes 5:101. https:\/\/doi.org\/10.1186\/s41687-021-00377-z","journal-title":"J Patient Rep Outcomes"},{"key":"11296_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2217\/cer-2020-0143","volume":"9","author":"FD Mowlem","year":"2020","unstructured":"Mowlem FD, Sanderson B, Platko JV, Byrom B (2020) Optimizing electronic capture of patient-reported outcome measures in oncology clinical trials: lessons learned from a qualitative study. J Comp Eff Res 9:1195\u20131204. https:\/\/doi.org\/10.2217\/cer-2020-0143","journal-title":"J Comp Eff Res"},{"key":"11296_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/op-24-00760","author":"S Katoju","year":"2025","unstructured":"Katoju S, Nguyen OT, Rajasekhara S, Hong YR, Alishahi Tabriz A, Turner K (2025) Participation in electronic patient-reported outcome measures collection as a part of routine supportive care delivery in oncology. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/op-24-00760","journal-title":"JCO Oncol Pract"},{"key":"11296_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110427","volume":"199","author":"G Heilemann","year":"2024","unstructured":"Heilemann G, Georg D, Dobiasch M, Widder J, Renner A (2024) Automation of ePROMs in radiation oncology and its impact on patient response and bias. Radiother Oncol 199. https:\/\/doi.org\/10.1016\/j.radonc.2024.110427","journal-title":"Radiother Oncol"},{"key":"11296_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","volume":"33","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D et al (2022) The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol 33:878\u2013892. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.007","journal-title":"Ann Oncol"},{"key":"11296_CR25","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/cncr.34844","volume":"129","author":"JR Cracchiolo","year":"2023","unstructured":"Cracchiolo JR, Arafat W, Atreja A, Bruckner L, Emamekhoo H, Heinrichs T et al (2023) Getting ready for real-world use of electronic patient-reported outcomes (ePROs) for patients with cancer: a National Comprehensive Cancer Network ePRO Workgroup paper. Cancer 129:2441\u20132449. https:\/\/doi.org\/10.1002\/cncr.34844","journal-title":"Cancer"},{"key":"11296_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101005","volume":"44","author":"MA Franzoi","year":"2024","unstructured":"Franzoi MA, Ferreira AR, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM et al (2024) Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. Lancet Reg Health Eur 44. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101005","journal-title":"Lancet Reg Health Eur"},{"key":"11296_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/op-24-00627","author":"GN Mody","year":"2025","unstructured":"Mody GN, Bennett AV, Stover AM, Jonsson M, Teal R, Vu M et al (2025) Implementation of symptom monitoring with electronic patient-reported outcomes: perspectives and recommendations from community oncology practices (Alliance AFT-39). JCO Oncol Pract. https:\/\/doi.org\/10.1200\/op-24-00627","journal-title":"JCO Oncol Pract"},{"key":"11296_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/cci.22.00187","volume":"7","author":"E Basch","year":"2023","unstructured":"Basch E, Rocque G, Mody G, Mullangi S, Patt D (2023) Tenets for implementing electronic patient-reported outcomes for remote symptom monitoring during cancer treatment. JCO Clin Cancer Inform 7. https:\/\/doi.org\/10.1200\/cci.22.00187","journal-title":"JCO Clin Cancer Inform"},{"key":"11296_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12885-021-07965-8","volume":"21","author":"R Knoerl","year":"2021","unstructured":"Knoerl R, Mazzola E, Hong F, Salehi E, McCleary N, Ligibel J et al (2021) Exploring the impact of a decision support algorithm to improve clinicians\u2019 chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. BMC Cancer 21:236. https:\/\/doi.org\/10.1186\/s12885-021-07965-8","journal-title":"BMC Cancer"},{"key":"11296_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J (2022) The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci 17. https:\/\/doi.org\/10.1186\/s13012-022-01245-0","journal-title":"Implement Sci"},{"key":"11296_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P et al (2021) Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials 18:104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120","journal-title":"Clin Trials"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11296-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:03:08Z","timestamp":1791486188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11296-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11296"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11296-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of\u00a0St. Vincent\u2019s Hospital (2020\/ETH02551).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from each participant.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1073"}}